---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-003304"
form_type: "8-K"
ticker: "XCUR"
cik: "0001698530"
company_name: "EXICURE, INC."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:12:15.919525+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Exicure licenses cavrotolimod patents to Bluejay for hepatitis treatment

## Summary
- Bluejay receives exclusive license in hepatitis field to Exicure's patents; small upfront payment made.
- Exicure eligible for modest royalties on future net sales of licensed technology.
- Exicure responsible for prosecution and maintenance of licensed patents.
- Cavrotolimod historically developed for oncology; repurposed for hepatitis by Bluejay.
- Bluejay is a private clinical-stage biopharma focused on viral and liver diseases.

## SEC filing metadata
- accession: 0001628280-24-003304
- form_type: 8-K
- ticker: XCUR
- cik: 0001698530
- company_name: EXICURE, INC.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1698530/000162828024003304/0001628280-24-003304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1698530/000162828024003304/xcur-20240205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-003304
- JSON: https://secwatch.observer/filing/0001628280-24-003304.json
- Plain text: https://secwatch.observer/filing/0001628280-24-003304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.